Treatment of benign cells with the cytokine led to increased proliferation and an epithelial-mesenchymal transition (EMT) phenotype, which suggests a role for IL6 in the earlier stages of prostate cancer [52]. The gene discussed is IL6; the disease is prostate carcinoma.